SGLT2 labels get new warnings

The U.S. Food and Drug Administration formally added warnings to the class labels for sodium‑glucose cotransporter‑2 (SGLT2) inhibitors about diabetic ketoacidosis and severe urinary tract infections. (fda.gov) The agency’s action follows a safety review of post‑market reports that began soon after the drugs reached the market in 2013. (ajmc.com) In the reports reviewed, investigators saw cases of ketoacidosis that differed from classic diabetic ketoacidosis because blood glucose was not always dramatically elevated—a presentation now widely called euglycemic DKA. (fda.gov) The same review found dozens of severe urinary and kidney infections that began as urinary tract infections and progressed to urosepsis or pyelonephritis, some requiring hospitalization or intensive care. (ajmc.com) SGLT2 inhibitors lower blood sugar by blocking glucose reabsorption in the kidney tubule, which produces persistent glycosuria. (ajmc.com) That glucose in the urine increases the local substrate for bacterial and fungal growth, explaining the rise in genital and urinary infections. (fda.gov) The mechanism behind ketoacidosis is less visually obvious but concrete: by shifting metabolism toward ketone production while lowering circulating glucose, SGLT2 inhibition can permit substantial ketogenesis without the severe hyperglycemia that usually alerts clinicians to DKA. (accessdata.fda.gov) The label language added explicit clinical steps. Patients with suggestive symptoms—nausea, vomiting, abdominal pain, fatigue, or difficulty breathing—are to stop the drug and seek urgent care. (fda.gov) Manufacturers were directed to run a five‑year pharmacovigilance study and to perform specialized follow‑up for reported DKA cases linked to the class. (ajmc.com) The FDA later translated safety signals into operational prescribing guidance: for elective surgery, the agency recommends stopping most SGLT2 agents at least three days beforehand (four days for ertugliflozin) to reduce the perioperative DKA risk. (fda.gov) For a patient‑safety leader, the label change matters in specific, executable ways. Regulatory teams must ensure company pharmacovigilance plans capture atypical DKA presentations and link those events to relevant procedures, fasting, or other stressors. (ajmc.com) Safety surveillance algorithms should flag normal‑glucose ketoacidosis terms, ketone testing results, and progression from UTI to sepsis, not rely solely on hyperglycemia codes. (accessdata.fda.gov) The FDA published the original safety announcement in December 2015 and has updated the prescribing information and guidance since then, embedding withholding intervals and ketone‑monitoring language into labels. (ajmc.com) The label changes formalize a predictable pattern from spontaneous reports into regulatory requirements: targeted follow‑up, revised prescriber advice, and concrete perioperative precautions that safety teams must operationalize in monitoring, case follow‑up, and risk‑minimization materials. (fda.gov)